Home Trials Genes Drugs 23andMe Graph Blog Contact

Home
Trials
Genes
Drugs
23andMe
Graph
Blog
Contact

Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

ClinicalTrials.gov
OpenTargets
ClinVar
PubChem

Links

Contact
Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “SMARCB1-deficient Renal Medullary Carcinoma”

4 trials

Filters

Phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Status

Recruiting

Active, Not Recruiting

Not Yet Recruiting

Completed

Enrolling by Invitation

Showing 4 of 4 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05286801

What this trial is testing

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Who this might be right for

Atypical Teratoid/Rhabdoid TumorEpithelioid SarcomaKidney Medullary Carcinoma+15 more

National Cancer Institute (NCI) 86

Testing effectiveness (Phase 2)Active Not RecruitingNCT06444880

What this trial is testing

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

Who this might be right for

SMARCB1-Deficient MalignanciesEpithelioid SarcomaRenal Medullary Carcinoma

M.D. Anderson Cancer Center 15

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07816770

What this trial is testing

MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary Carcinomas

Who this might be right for

Metastatic Non-Clear Cell Renal Cell CarcinomaMetastatic Renal Medullary Carcinomas

Fudan University 30

Testing effectiveness (Phase 2)Looking for participantsNCT07438626

What this trial is testing

Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma

Who this might be right for

Phase IISacituzumabTirumotecan+1 more

M.D. Anderson Cancer Center 20